P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

Clinical trial NCT05905055 · COMPLETED

Trial details

NCT number: NCT05905055
Sponsor: Meiji Seika Pharma Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Complicated Urinary Tract Infection Acute Pyelonephritis Hospital-acquired Bacterial Pneumonia Ventilator-associated Bacterial Pneumonia Complicated Intra-abdominal Infection

Start date: 2023-09-22
Primary completion: 2025-09-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.